Riot Platforms (RIOT) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants Phil McPherson - VP of Capital Markets & Investor RelationsJason Les - CEOColin Yee - Executive VP & CFOJason Chung - Executive VP and Head of Corporate Development & StrategyBenjamin Sommers - Equity Research AssociateReginald Smith - Senior AssociateMartin Toner - Managing Director - Institutional Research, Growth & InnovationMike Grondahl - Head of Equities & Director of Research Conference Call Participants Nick Gi ...

Tarsus Pharmaceuticals (TARS) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants David Nakasone - Head of Investor Relations (IR)Bobak Azamian - Co-Founder, President, CEO & ChairmanAziz Mottiwala - Chief Commercial OfficerJeff Farrow - CFO and CSOSesha Neervannan - COOAndrea Newkirk - Biotechnolgy Equity ResearchEddie Hickman - Vice President Conference Call Participants Lachlan Hanbury-Brown - Biotech Equity Research AnalystPavan Patel - AnalystCory Jubinville - Managing Director & Resear ...

El Pollo Loco (LOCO) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants Ira Fils - Chief Financial OfficerElizabeth Williams - CEO & DirectorAndy Barish - Managing Director Conference Call Participants Jeremy Hamblin - Senior Research AnalystJake Bartlett - Senior Equity Research Analyst Operator Good day ladies and gentlemen and thank you for standing by. Welcome to the El Polo Loco First Quarter twenty twenty five Earnings Conference Call. At this time, all participants have been placed i ...

Five9 (FIVN) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants Emily Greenstein - DirectorMike Burkland - Chairman and Chief Executive OfficerAndy Dignan - PresidentBryan Lee - Interim CFORobert Morelli - Equity Research AssociateSiti Panigrahi - Managing DirectorRaimo Lenschow - Managing DirectorRobert Dee - Equity Research AssociatePeter Levine - Managing DirectorWillow Miller - Equity Research AssociateCatharine Trebnick - Managing DirectorSamad Samana - Managing DirectorThomas Blakey - ...

BigBear.ai Holdings (BBAI) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants None - ExecutiveKevin McAleenan - CEO & DirectorJulie Peffer - Chief Financial Officer Operator Greetings, and welcome to the Big Bear AI Holdings Incorporated First Quarter twenty five Earnings Call and Webcast. At this time, all participants are in a listen only mode. As a reminder, this conference is being recorded. It is now my pleasure to introduce David Cronlow. Thank you, David. You may begin. None Thank yo ...

ICF International (ICFI) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants Lynn Morgen - PartnerJohn Wasson - Chairman, President & CEOBarry Broadus - Senior VP & CFOTim Mulrooney - Group Head–Global ServicesJoseph Vafi - Managing Director, Equity ResearchTobey Sommer - Managing DirectorKevin Steinke - Managing Director Conference Call Participants Marc Riddick - Business Services Analyst Operator Welcome to the First Quarter twenty twenty five ICF Earnings Conference Call. My name is Cori ...

Financial Data and Key Metrics Changes - The company reported first quarter revenue of $66.1 million, reflecting a 9% year-over-year increase [12] - Gross margin for the quarter was 80.9%, consistent with the target range of 80% to 82% [16] - Non-GAAP net income for the quarter was $15 million, or $0.20 per diluted share, compared to $12.7 million, or $0.17 per diluted share in the same quarter last year [16] - Cash from operations generated during the quarter was $15.2 million, normalizing in line with historical patterns [17] Business Line Data and Key Metrics Changes - Enterprise revenue grew by 18% year-over-year, while service provider revenue increased by 3% [5][12] - On a trailing twelve-month basis, enterprise revenue increased by 12%, indicating a solid foundation for future growth [6] - Product revenue constituted 54% of total revenue, while services revenue made up 46% [13] Market Data and Key Metrics Changes - North America showed relatively strong performance, while Asia Pacific results were impacted by a strong Q1 last year due to large infrastructure projects in Japan [13] - Overall market conditions have improved and stabilized, with service provider customer growth driven by demand for greater data center capacity [7][11] Company Strategy and Development Direction - The company is focusing on expanding its presence and capabilities with enterprise customers, particularly through the acquisition of ThreatX Protect to enhance its cybersecurity portfolio [8][9] - The rise of AI is driving demand in the enterprise segment, reinforcing the strategic position of the company [10] - The company aims to maintain a strong balance sheet while navigating market volatility and returning capital to shareholders [11][19] Management's Comments on Operating Environment and Future Outlook - Management noted that while there may be delays in order timing due to market conditions, these are expected to be temporary [6] - The company is comfortable with expectations of high single-digit revenue growth for the year, pending macroeconomic conditions [35] - Management emphasized the importance of aligning with AI trends and maintaining a competitive edge in the market [21] Other Important Information - Total deferred revenue increased by 8% to $152.7 million, indicating greater visibility into future revenues [14] - The company has authorized a new $75 million share repurchase program, following nearly exhausting the previous authorization [19] Q&A Session Summary Question: Impact of tariffs on customer conversations - Management indicated that there is caution among customers regarding macroeconomic conditions, but spending patterns are not completely frozen [27][29] Question: Visibility on large customer initiatives for AI data centers - Management noted reasonable visibility into large AI build-outs, with companies modulating their plans based on financials [30][31] Question: Anticipation of high single-digit revenue growth - Management expressed comfort with the expectation of high single-digit revenue growth, pending macroeconomic shifts [35] Question: Competitive landscape in data center capacity - Management stated that the competitive dynamic remains consistent, with partnerships evolving as service providers build AI data centers [36] Question: Growth dynamics in enterprise revenue - Management clarified that the growth in enterprise revenue is reflective of a soft Q1 last year, with multiple customers contributing to the increase [41] Question: Caution among service provider customers - Management indicated that caution is broad-based among service providers, although some are more aggressive in their spending [42][43] Question: Sales and marketing expenses - Management explained that the decrease in sales and marketing expenses is part of cost management to maintain EBITDA margins while investing in R&D [44] Question: Full year EBITDA target - Management remains confident in achieving the target EBITDA margin of 26% to 28% despite potential fluctuations in input costs [49][50] Question: Diversification of contract manufacturing partners - Management is actively working on building a more resilient and flexible global footprint for manufacturing [51][52] Question: Exchange rate impacts - Management acknowledged that exchange rate fluctuations could pose revenue risks, but project timelines are primarily driven by customer needs [55]

Viavi Solutions (VIAV) Q3 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants Vibhuti Nayar - Director of Investor RelationsIlan Daskal - Executive VP & CFOOleg Khaykin - President and CEORuben Roy - Managing Director - Equity ResearchAndrew Spinola - DirectorMichael Genovese - Senior managing director and senior research analyst Conference Call Participants Ryan Koontz - Senior AnalystNone - AnalystTim Savageaux - MD & Senior Research Analyst Operator Good afternoon. My name is Audra, and I wi ...

Financial Data and Key Metrics Changes - Total revenue for the first quarter was $52.4 million, representing a 25% growth from the same period last year [22] - MRD revenue grew 34% year-over-year to $43.7 million, with clinical and pharma contributions of 65% and 35% respectively [22] - Sequencing gross margin improved by 17 percentage points year-over-year to 62% [8][22] - Operating expenses decreased by 9% to $82 million, driven by lower R&D spending [23] - Cash burn for the quarter was $23 million, a 38% improvement compared to the same period last year [8] Business Line Data and Key Metrics Changes - ClonoSEQ clinical revenue grew 55% year-over-year, with test deliveries reaching over 23,000, a 36% increase [10] - Average selling price (ASP) for ClonoSEQ tests in the US increased by 14% to over $1,220 per test [13] - MRD Pharma revenue grew 11% year-over-year, with $4.5 million recognized in regulatory milestones [14] Market Data and Key Metrics Changes - The number of ordering healthcare providers grew 31% year-over-year, now exceeding 3,400 [12] - Blood-based testing contributed 44% of MRD tests in the US, up from 39% a year ago [11] Company Strategy and Development Direction - The company is focused on increasing the lifetime value of each clonoSEQ Medicare patient and expanding its market presence through EMR integrations [9][12] - Strategic goals include achieving over 45% of clonoSEQ testing done in blood and launching new initiatives in the second half of the year [16] - The company aims to be adjusted EBITDA positive in the second half of the year [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving raised full-year guidance due to strong first-quarter performance and sustained momentum [29] - The company has minimal exposure to tariffs and NIH funding pressures, providing a solid cash position of $233 million [9] Other Important Information - The company is on track to lower its full-year total operating expense guidance to a range of $335 million to $345 million [26] - Full-year cash burn guidance has been lowered to a range of $50 million to $60 million [27] Q&A Session Summary Question: Specific indications seeing growth and contribution trends - Management noted strong sequential growth across all indications, particularly in lymphoma indications like DLBCL and MCL [32] Question: Updates on EMR integration and larger accounts - Management reported significant growth in accounts integrated for over a year, with some larger accounts showing an average quarter-over-quarter growth of 27% [37] Question: Drivers of clonoSEQ volume growth - Management indicated that growth was driven by non-Hodgkin's lymphoma indications and the acceleration of EMR integrations [42] Question: Milestone payments and funnel growth - Management confirmed that more milestones are becoming available, providing clarity and confidence in the 2025 outlook [48] Question: Pricing and contracting discussions - Management emphasized a disciplined approach to pricing, ensuring contracted rates are close to Medicare rates [51] Question: Frequency of testing in clinical trials - Management acknowledged increased interest in more frequent testing, particularly in multiple myeloma trials [58] Question: Operational efficiencies from EMR integrations - Management noted potential operational efficiencies from EMR integrations, with significant reductions in callbacks reported by integrated accounts [68] Question: NeoGenomics partnership progress - Management provided updates on the partnership, focusing on optimizing the broader national launch based on insights gained from phase one accounts [115]

NV5 Global (NVEE) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants Richard Tong - Director, EVP & General CounselDickerson Wright - Executive ChairmanBen Heraud - CEOEdward Codispoti - CFOAlexander Hockman - President & CEO - InfrastructureAndrew Chang - COO - Buildings & TechnologyKurt Allen - President of GeospatialSam Kusswurm - Equity Research Associate Conference Call Participants Chris Moore - Senior AnalystRob Brown - Founding Partner & Senior Research AnalystAndrew Wittmann - Seni ...